Advertisement

Objectives and achievements of regulations in developing countries

  • D. C. Jayasuriya
Part of the CMR Workshop Series book series (CMRWS)

Abstract

  1. 1.

    A major objective for most developing countries is to ascertain what is on the market and to prepare an inventory. Developing countries have adopted different methods to register drugs.

     
  2. 2.

    The role of the WHO Certification Scheme on the Quality of Pharmaceutical Products, in assisting countries to develop and update registration systems, has not yet been fully appreciated.

     
  3. 3.

    In formulating the criteria for drag registration, some countries are under pressure to adopt a ‘need clause’ as in Norway. However, given adverse balance of payments and other foreign exchange problems, more and more countries are likely to consider the price of the drug as a critical factor in the registration process.

     
  4. 4.

    Whilst modest attempts are underway to develop the local production of drugs, lack of resources for the enforcement of good manufacturing practice is a major impediment.

     
  5. 5.

    In many developing countries there is an urgent need to improve supply systems and this has resulted in diverting scarce resources which could have been deployed for regulatory purposes.

     
  6. 6.

    Countries with limited resources need to be encouraged to develop innovative regulatory systems which are tailor-made to local needs.

     

Keywords

Good Manufacturing Practice Regulatory Decision Certification Scheme Essential Drug Bulk Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chiodomere E C (1984). Drug regulation in African countries: needs and expectations. Pharmacy International, 5(2), 37Google Scholar
  2. 2.
    Expert Committee of the Government of Bangladesh (1982). Report on Evaluation of Registered/Licensed Products and Draft National Drug Policy, Dacca p92Google Scholar
  3. 3.
    Jayasuriya D C (1985). Regulation of Pharmaceuticals in Developing Countries: Legal Issues and Approaches. (Geneva: World Health Organization)Google Scholar
  4. 4.
    Jayasuriya D C and Yeap Boon Chye (1987). Malaysia’s New Drug Regulations: Progress Through Co-operation. (Washington, Pharmaceutical Manufacturers Association) pp. 14–6Google Scholar
  5. 5.
    Jayasuriya D C (1985). The Public Health and Economic Dimensions of the New Drug Policy of Bangladesh. (Washington, Pharmaceutical Manufacturers Association)Google Scholar
  6. 6.
    Drugs (Control) Ordinance No VIII (1982). Ministry of Health and Population Control, BangladeshGoogle Scholar
  7. 7.
    Chetley A (1985). Drug production with a social conscience: the experience of Gonoshasthaya Pharmaceuticals. Development Dialogue, 2, 100Google Scholar
  8. 8.
    World Health Organization (1987). Sources, Types and Availability of Information Concerning the Use of Drugs. In: The Rational Use of Drugs, pp. 96–108. (Geneva: WHO)Google Scholar
  9. 9.
    Patel M (1983). Drug costs in developing countries and policies to reduce them. World Development, 11 (3), 195–204CrossRefGoogle Scholar
  10. 10.
    Dukes M N G (1985). The Effects of Drug Regulations, pp. 45–6. (Lancaster: MTP Press)Google Scholar
  11. 11.
    UNIDO (1978). Growth of the Pharmaceutical Industry in Developing Countries: Problems and Prospects. (Vienna, United Nations Industrial Development Organization)Google Scholar
  12. 12.
    WHO, DANIDA and SIDA (1984). Report of a Project Preparation Mission on Essential Drugs for Primary Health Care in Bangladesh p. 12Google Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • D. C. Jayasuriya

There are no affiliations available

Personalised recommendations